| Literature DB >> 35208939 |
Nur Farisya Shamsudin1, Qamar Uddin Ahmed1, Syed Mahmood2,3, Syed Adnan Ali Shah4,5, Alfi Khatib1, Sayeed Mukhtar6, Meshari A Alsharif7, Humaira Parveen6, Zainul Amiruddin Zakaria8.
Abstract
According to the latest report released by the World Health Organization, bacterial resistance to well-known and widely available antibacterial drugs has become a significant and severe global health concern and a grim challenge to tackle in order to cure infections associated with multidrug-resistant pathogenic microorganisms efficiently. Consequently, various strategies have been orchestrated to cure the severe complications related to multidrug-resistant bacteria effectively. Some approaches involved the retardation of biofilm formation and multidrug-resistance pumps in bacteria as well as the discovery of new antimicrobial agents demonstrating different mechanisms of action. In this regard, natural products namely alkaloids, terpenoids, steroids, anthraquinone, flavonoids, saponins, tannins, etc., have been suggested to tackle the multidrug-resistant bacterial strains owing to their versatile pharmacological effects. Amongst these, flavonoids, also known as polyphenolic compounds, have been widely evaluated for their antibacterial property due to their tendency to retard the growth of a wide range of pathogenic microorganisms, including multidrug-resistant bacteria. The hydroxylation of C5, C7, C3', and C4'; and geranylation or prenylation at C6 have been extensively studied to increase bacterial inhibition of flavonoids. On the other hand, methoxylation at C3' and C5 has been reported to decrease flavonoids' antibacterial action. Hence, the latest information on the antibacterial activity of flavonoids is summarized in this review, with particular attention to the structure-activity relationship of this broad class of natural compounds to discover safe and potent antibacterial agents as natural products.Entities:
Keywords: antibacterial effects; flavonoids; natural products; pharmacophores; structure activity relationship studies
Mesh:
Substances:
Year: 2022 PMID: 35208939 PMCID: PMC8879123 DOI: 10.3390/molecules27041149
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Various classes of flavonoids.
Figure 2Basic skeleton and numbering system of flavonoids.
Isolated compounds from Laurus nobilis were shown to demonstrate potent antibacterial activity against MRSA strains.
| Com. No. | R | Anti-MRSA Activity (MIC: μg/mL) | ||||||
|---|---|---|---|---|---|---|---|---|
| MRSA Strains | ||||||||
| OM481 | OM505 | OM584 | OM623 | * COL | N315 | 209P | ||
|
| α-L-(2‴,4‴-di- | 1 | 1 | 2 | 2 | 1 | 1 | 0.5 |
|
| α-L-(2″- | 1 | 2 | 2 | 2 | 1 | 1 | 0.5 |
| Oxacillin | - | 512 | 128 | 256 | 256 | 512 | 8 | 0.13 |
| Ciprofloxacin | - | 8 | 1 | 16 | 8 | <0.13 | 0.25 | <0.13 |
| Norfloxacin | - | 128 | 8 | 64 | 64 | 1 | 2 | 0.5 |
| Erythromycin | - | >1024 | >128 | >1023 | >128 | >0.12 | >1024 | 2 |
| Tetracycline | - | 4 | 0.25 | 128 | 64 | 128 | 0.13 | 0.13 |
* Kaempferol 3-O-α-l-(2‴,4‴-di-E-p-coumaroyl)-rhamnoside (1a) and Kaempferol 3-O-α-l-(2″-Z-p-coumaroyl-4‴-E-p-coumaroyl)-rhamnoside (1b); * COL, Colindale.
Figure 3SAR analysis of tested flavonoids [70].
Isolated compounds from Paulownia tomentosa were showed to display potent antibacterial activity against several Gram-positive strains.
| Com. No. | R1 | R2 | R3 | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|
| * B.c | * B.s | * E.f | * L.m | * S.a | * S.e | ||||
|
| H | OMe | OH | 4 | 4 | 4 | 4 | 2 | 4 |
|
| H | OMe | OMe | 4 | 4 | 4 | 4 | 4 | 4 |
|
| OH | OMe | H | 2 | 4 | 4 | 2 | 2 | 2 |
|
| H | OMe | H | 4 | 8 | 8 | 4 | 8 | 4 |
|
| H | H | H | 4 | 4 | 4 | 4 | 8 | 4 |
|
| H | OH | H | 4 | 4 | 4 | 4 | 4 | 4 |
| Ciprofloxacin and nystatin | - | - | - | 1 | 2 | 1 | 1 | 0.5 | 1 |
* 3′-O-methyl-5′-hydroxydiplacone (2a), 3′-O-methyl-5′-O-methyldiplacone (2b), 3′-O-Methyldiplacol (2c), 3′-O-Methyldiplacone (2d), mimulone (2e), and diplacone (2f); * B.c., Bacillus cereus; B.s., Bacillus subtilis; E.f., Enterococcus faecalis; L.m., Listeria monocytogenes; S.a., S. aureus; S.e., Staphylococcus epidermidis.
Figure 4SAR analysis of isolated flavonoids from Paulownia tomentosa [71].
Figure 5The SAR of flavonoids as antibacterial agents by inhibiting the DNA gyrase activity [62].
Flavonoids compounds displayed good E. coli DNA gyrase inhibition.
| Flavonoids | R1 | R2 | R3 | R4 | R5 | R6 | R7 | R8 | MIC50 (μg/mL) |
|---|---|---|---|---|---|---|---|---|---|
| Tangeritin | H | OMe | OMe | OMe | OMe | H | OMe | H | 137 |
| 5,6,7,4′-tetramethoxyflavone | H | OMe | OMe | OMe | H | H | OMe | H | 156 |
| Nobiletin | H | OMe | OMe | OMe | OMe | OMe | OMe | H | 177 |
| Chrysin | H | OH | H | OH | H | H | H | H | 37 |
| Galangin | OH | OH | H | OH | H | H | H | H | 53 |
| Quercetin | OH | OH | H | OH | H | OH | OH | H | 36 |
| Baicalein | H | OH | OH | OH | H | H | H | H | 71 |
| Luteolin | H | OH | H | OH | H | OH | OH | H | 67 |
| Kaempferol | OH | OH | H | OH | H | H | OH | H | 25 |
| Myricetin | OH | OH | H | OH | H | OH | OH | OH | 142 |
Antibacterial activity of several flavones and isoflavones against E. coli via membrane interaction effect.
| Flavones/Flavonols | MIC50 (μg/mL) | Isoflavones | MIC50 (μg/mL) |
|---|---|---|---|
| Chrysin | 36.72 | Daidzein | 120.0 |
| Kaempferol | 25.00 | Puerarin | 1500 |
| 5,6,7,4′-tetramethoxyflavone | 156.3 | Genistin | 238.0 |
| Luteolin | 67.25 | Ononin | 712.5 |
| Baicalein | 70.94 | ||
| Quercetin (Flavonol) | 35.76 | ||
| Tangeritin | 137.1 |
Figure 6The SAR of flavonoids as antibacterial by inhibiting the growth of E. coli [73].
Figure 7Chemical structures of several tested flavonoids and their specific structural requirements for antitubercular activity (Mycobacterium tuberculosis) [74].
Figure 8The structural-activity analysis of 4-thioflavones and 4-iminoflavones [75].
Antibacterial activity of flavanones and flavones against Gram-positive and Gram-negative bacteria.
| Flavonoids | MIC (μg/μL) | |||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
| Naringenin | 2 | 4 | >4 | 2 | 2 | 2 | 2 | >4 |
| Pinocembrin | 1 | 4 | 1 | 4 | 2 | 1 | 1 | >4 |
| 7- | 2 | 4 | >4 | 0.5 | 2 | 1 | 2 | 4 |
| Quercetin | >4 | >4 | >4 | 0.5 | 2 | 2 | >4 | 2 |
| Galangin | 1 | 1 | 0.5 | 0.25 | 0.25 | 0.25 | 0.25 | 0.5 |
| 3- | >4 | >4 | >4 | >4 | 2 | 1 | >4 | >4 |
| 3- | 1 | 0.5 | 0.5 | 0.25 | 0.25 | 0.38 | 0.38 | 0.5 |
| 3,7- | >4 | >4 | >4 | >4 | >4 | >4 | >4 | >4 |
Figure 9Chemical structure of several tested flavonoids and the SAR of flavonoids studied for antibacterial properties against four Gram-positive and four Gram-negative bacteria [76].
Figure 10Chemical structures of several tested chalcones and SAR of chalcones for antibacterial activity [77].
Antibacterial activity of some selected flavonoids against several antibiotic resistant bacteria.
| Flavonoids | MIC (μg/mL) | ||
|---|---|---|---|
| MRSA | VRE |
| |
| Luteolin | 512 | >512 | >512 |
| Datiscetin | 512 | >512 | >512 |
| Kaempferol | >512 | >512 | >512 |
| Quercetin | 256 | 512 | >512 |
| Myricetin | 128 | 128 | 32 |
Figure 11Chemical structures of tested flavonoids that were active and the structural feature requirements for the manifestation of flavonoids’ antibacterial activity against antibiotic resistant bacteria [64].
Antibacterial activity of flavonoids isolated from Psoralea corylifolia seeds.
| Flavonoids | MIC (mM) | Flavonoids | MIC (mM) | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Corylifol A | 0.147 | 0.147 | Bavachin | 0.037 | 0.037 |
| Corylifol B | 0.037 | 0.037 | Bavachinin | 0.018 | 0.018 |
| Corylifol C | >0.147 | >0.147 | Corylin | >0.147 | >0.147 |
| Neobavaisoflavone | 0.037 | 0.037 | 1-[2,4-dihydroxy-3-(2-hydroxy-3-methyl-3-butenyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one | >0.147 | >0.147 |
| Isobavachalcone | 0.018 | 0.009 | 8-prenyldaidzein | >0.147 | >0.147 |
| 7,8-dihydro-8-(4-hydroxyphenyl)-2,2-dimethyl-2H,6H-benzo[1,2- | 0.037 | 0.037 | Bakuchalcone | >0.147 | >0.147 |
| Isoneobavaiso-flavone | 0.073 | 0.037 | Brosimacutin G | >0.147 | >0.147 |
| Bavachalcone | 0.037 | 0.018 | Erythrinin A | 0.018 | 0.018 |
| Bakuchiol (Control) | 0.037 | 0.018 | Magnolol (Control) | 0.037 | 0.018 |
Figure 12Chemical structures of isolated flavonoids that have excellent inhibition and the summary of important structural features of flavonoids as antibacterial agents isolated from Psoralea corylifolia seeds [78].
Figure 13Important SAR of flavonoids as antibacterial agent against MRSA [79].
Figure 14Chemical structures of mentioned flavonoids and their related SAR for antibacterial activity [80].
Antibacterial activities of naturally occurring isoflavones 3a–o.
| Com. No. | R1 | R2 | R3 | R4 | R5 | R6 | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| * B.e | * E.f | * L.m | * S.a | * S.e | * S.p | |||||||
|
| H | OMe | OH | H | H | OMe | - | - | - | - | - | - |
|
| H | OMe | OMe | H | H | OMe | - | - | - | - | - | - |
|
| H | H | OMe | H | H | OMe | - | - | - | - | - | - |
|
| OMe | H | H | OMe | H | OMe | - | - | - | - | - | - |
|
| H | OMe | OH | H | H | H | - | - | - | - | - | - |
|
| H | OH | OH | H | H | OH | 32 | - | 128 | 16 | 32 | 64 |
|
| H | H | OH | H | OH | OH | - | 128 | 128 | - | - | - |
|
| OH | H | OMe | H | H | OMe | - | - | - | - | - | - |
|
| OH | H | OH | H | H | OMe | 64 | - | 64 | - | - | 32 |
|
| H | H | OH | OH | H | OH | - | - | - | - | 128 | - |
|
| OH | H | OMe | H | H | OH | - | - | - | - | - | - |
|
| H | OMe | OH | H | H | OH | - | - | - | - | - | - |
|
| H | H | OH | H | H | OH | - | - | - | - | - | - |
|
| OH | H | OH | H | H | OH | 128 | - | - | - | - | 64 |
|
| H | H | OH | H | H | OMe | - | - | - | - | - | - |
* 6,4′-dimethoxy-7-hydroxyisoflavone (3a), 6,7,4′-trimethoxyisoflavone (3b), 7,4′-dimethoxyisoflavone (3c), 5,7,4′-trimethoxyisoflavone (3d), 7-hydroxy-6methoxyisoflavone (3e), 6,7,4′-trihydroxyisoflavone (3f), 7,3′,4′-trihydroxyisoflavone (3g), 7,4′-dimethoxy-5-hydroxyisoflavone (3h), 5,7-dihydroxy-4′-methoxyisoflavone (3i), 7,8,4′-trihydroxyisoflavone (3j), 5,4′-dihydroxy-7-methoxyisoflavone (3k), 7,4′-dihydroxy-6-methoxyisoflavone (3l), 7,4′-dihydroxyisoflavone (3m), 5,7,4′-trihydroxyisoflavone (3n), and 7-hydroxy-4′-methoxyisoflavone (3o); * B.c., B. cereus; E.f., E.s faecalis; L.m., L. monocytogenes; S.a., S. aureus; S.e., S. epidermidis; S.p., Streptococcus pyogenes.
Figure 15SAR of isoflavones as antibacterial agent [81].
Chalcones (4a–k) showed good antibacterial activity against Gram-positive bacteria.
| Com. No. | R1 | R2 | R3 | R4 | MIC (μg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
| MSSA | MRSA | |||||||
|
| OH | OH |
| - | 100 | 3.13 | 1.56 | 1.56 | >200 | 1.56 |
|
| MOMO | OH |
| 100 | >200 | >200 | >200 | >200 | 25 | |
|
| OH | OH |
| OH | >200 | 25 | >200 | 200 | >200 | 6.25 |
|
| OH | OH |
| - | 200 | 12.5 | 6.25 | 0.39 | >200 | 3.13 |
|
| OH | OH |
| - | >200 | 1.56 | 3.13 | 0.78 | >200 | >200 |
|
| OH | OH |
| - | >200 | 1.56 | 25 | 6.25 | >200 | >200 |
|
| OH | OH |
| - | 100 | 25 | 3.13 | 3.13 | >200 | 12.5 |
|
| OH | OH |
| OH | >200 | 50 | >200 | 25 | >200 | 12.5 |
|
| OH | - |
| - | 200 | 100 | 12.5 | 6.25 | >200 | 6.25 |
|
| OH | OH |
| - | 50 | >200 | 6.25 | 12.5 | >200 | 3.13 |
|
| OH | OH |
| - | 50 | 100 | 25 | >200 | >200 | >200 |
* (E)-1-(2,4-Dihydroxyphenyl)-3-(6,6-dimethylbicyclo[3.1.1]-hept-2-en-2-yl)prop-2-en-1-one (4a), (E)-3-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)-1-(2-hydroxy-4-(methoxymethoxy)phenyl)prop-2-en-1-one (4b), (E)-3-(6,6-Dimethylbicyclo[3.1.1]hept-2-en-2-yl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (4c), (E)-3-(2-(Allyloxy)phenyl)-1(2,4-dihydroxyphenyl)prop-2-en-1-one (4d), (E)-1-(2,4-Dihydroxyphenyl)-3-(2-(hexyloxy)phenyl)prop-2-en-1-one (4e), (E)-1-(2,4-Dihydroxyphenyl)-3-(2-(octyloxy)phenyl)prop-2-en-1-one (4f), (E)-1-(2,4-Dihydroxyphenyl)-3-(4-(piperidin-1-yl)phenyl)prop-2-en-1-one (4g), (E)-3-(2-(Allyloxy)phenyl)-1-(2,4,6-trihydroxyphenyl)prop-2-en-1-one (4h), (E)-3-(2-(Allyloxy)phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (4i), (E)-3-(3-(Allyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (4j), and (E)-3-(4-(Allyloxy)phenyl)-1-(2,4-dihydroxyphenyl)prop-2-en-1-one (4k).
Figure 16The chemical structure and SAR of chalcones tested [82].
Figure 17Chemical structures of Balsacone R and Balsacone Q, with the SAR of balsacones for their anti-MRSA activity [83].
Anti-MRSA activities of flavonoids isolated from Kenyan plants.
| Com. No. | R1 | R2 | R3 | R4 | MIC (μg/mL) | |||
|---|---|---|---|---|---|---|---|---|
| MRSA3 | MRSA4 | MRSA6 | MRSA8 | |||||
|
| OH | OH | H | OMe | - | 64 | 128 | - |
|
| OMe | OH | OMe | OH | 128 | 16 | 32 | 64 |
|
| OCOMe | OMe | H | OCOMe | - | 128 | - | - |
* 3′,5′-dihydroxy-1′-methoxychalcone (5a), 1′,3′-dihydroxy-2′,5′-dimethoxychalcone (5b), 1,5-diacetate-3′-methoxychalcone (5c).
Figure 18Structural activity of chalcones against MRSA strains [84].
Figure 19The chemical structures of biflavonoids isolated from Schinus terebinthifolius Raddi fruits [85].
Figure 20The chemical structure of tested flavonoids [86].
Antibacterial activities of isobavachalcone and α-mangostin against multidrug resistant bacterial strains.
| Compounds | MIC (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|
| MRSA | MRSA |
| VRE | VRE | ||||
| α-mangostin | 1 | 1 | 0.5 | 0.5 | 0.5 | 2 | >128 | >128 |
| Isobavachalcone | 4 | 4 | 4 | 8 | 4 | 1 | >128 | >128 |
| Vancomycin | 1 | 0.5 | 1 | >128 | >128 | >128 | >128 | >128 |
Figure 21α-mangostin, isobavachalcone and structural feature responsible for antibacterial activity [65].
Antibacterial activities of novel sulfur-containing tricyclic flavonoids (6a–h) against S. aureus and E. coli.
| Com. No. | R1 | R2 | R3 | MIC (μg/mL) | |
|---|---|---|---|---|---|
|
|
| ||||
|
| H | Br | Cl | 0.48 | 3.9 |
|
| H | Br | OMe | 1.95 | 125 |
|
| I | I | Cl | 0.97 | 15.62 |
|
| Br | Br | Cl | 1.95 | 7.81 |
|
| H | H | Cl | 1.95 | 62.5 |
* 8-bromo-4-(4-chlorophenyl)-N,N-diethyl-4H-[1,3]dithiolo[4,5-c]chromen-2-amine (6a), 8-bromo-N,N-diethyl-4-(4-methoxyphenyl)-4H-[1,3]dithiolo[4,5-c]chromen-2-amine (6b), 4-(4-chlorophenyl)-N,N-diethyl-6,8-diiodo-4H-[1,3]dithiolo[4,5-c]chromen-2-amine (6c), 6,8-dibromo-4-(4-chlorophenyl)-N,N-diiethyl-4H-[1,3]dithiolo[4,5-c]chromen-2-amine (6d), and 4-(4-chlorophenyl)-N,N-diethyl-4H-[1,3]dithiolo[4,5-c]chromen-2-amine (6e).
Figure 22Summary of SAR of sulfur-containing tricyclic flavonoids against S. aureus and E. coli [88].
Figure 23SAR analysis of sulfur-containing tricyclic flavonoids against S. aureus and E. coli [89].
Sulfur-containing tricyclic flavonoids (7a–m) as antibacterial agent.
| Com. No. | R1 | R2 | R3 | MIC (μg/mL) | Com. No. | R1 | R2 | R3 | MIC (μg/mL) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||||
|
| Br | NMe2 | Cl | 7.81 | 15.62 |
| I | NEt2 | Cl | 0.48 | 3.9 |
|
| Br | Pyrrolidine | Cl | 1.95 | 3.90 |
| I | NEt2 | Br | 0.48 | 3.9 |
|
| Br | Piperidine | Cl | 62.5 | 125 |
| I | NEt2 | I | 0.48 | 3.9 |
|
| Br | NEt2 | F | 1.95 | 15.62 |
| I | NEt2 | H | 0.97 | 7.81 |
|
| Br | NEt2 | Br | 0.48 | 3.9 |
| H | NEt2 | H | 62.5 | 62.5 |
|
| Br | NEt2 | I | 0.48 | 3.9 | Kanamycin | - | - | - | 1.95 | 7.81 |
|
| Br | NEt2 | H | 1.95 | 7.81 | Ampicillin | - | - | - | 7.81 | 7.81 |
|
| I | NEt2 | F | 1.95 | 7.81 | ||||||
* 2-N,N-Dimethylamino-8-bromo-4-(4-chlorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7a), 2-(Pyrrolidin-1-yl)-8-bromo-4-(4-chlorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7b), 2-(Piperidin-1-yl)-8-bromo-4-(4-chlorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7c), 2-N,N-Diethylamino-8-bromo-4-(4-fluorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7d), 2-N,N-Diethylamino-8-bromo-4-(4-bromophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7e), 2-N,N-Diethylamino-8-bromo-4-(4-iodophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7f), 2-N,N-Diethylamino-8-bromo-4-phenyl-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7g), 2-N,N-Diethylamino-8-iodo-4-(4-fluorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7h), 2-N,N-Diethylamino-8-iodo-4-(4-chlorophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7i), 2-N,N-Diethylamino-8-iodo-4-(4-bromophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7j), 2-N,N-Diethylamino-8-iodo-4-(4-iodophenyl)-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7k), 2-N,N-Diethylamino-8-iodo-4-phenyl-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7l), and 2-N,N-Diethylamino-4-phenyl-4H-1,3-dithiol[4,5-c]chromen-2-ylium tetrafluoroborate (7m).
Antibacterial activity of chalcones (8a–c) against S. aureus.
| Com. No. | R | Antibacterial Action against | |
|---|---|---|---|
| Inhibition Zone (mm) | MIC (ppm) | ||
|
| H | 11 | 92 |
|
| F | 13 | 88 |
|
| Cl | 9 | 93 |
| Ampicillin | - | 11 | - |
* 4-((E)-3-Oxo-3-phenylprop-1-enyl)benzoic acid (8a), 4-((E)-3-(4-Fluorophenyl)-3-oxoprop-1-enyl)benzoic acid (8b), and 4-((E)-3-(4-Chlorophenyl)-3-oxoprop-1-enyl)benzoic acid (8c).
Figure 24SAR of chalcones against S. aureus [92].
Antibacterial activity of the substituted chalcones contaning nitor, amino, hydroxyl, methoxy, and chloro groups (9a–n).
| Com. No. | R1 | R2 | R3 | R4 | R5 | R6 | MIC (μg/mL) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
| |||||||
|
| NO2 | H | H | OH | H | H | 4.64 | 4.64 | 2.32 | 1.16 | 2.32 |
|
| NO2 | H | NO2 | H | H | H | 16.76 | 4.19 | 1.05 | 2.10 | 4.19 |
|
| NO2 | H | OMe | OMe | OMe | H | 3.64 | 1.82 | 1.82 | 1.82 | 3.64 |
|
| NO2 | NO2 | H | H | H | H | 2.10 | 4.19 | 2.10 | 2.10 | 4.19 |
|
| NO2 | H | OEt | OH | H | H | 1.00 | 3.99 | 3.99 | 1.99 | 1.99 |
|
| NO2 | H | OMe | OH | H | H | 4.18 | 2.09 | 2.09 | 2.09 | 4.18 |
|
| NO2 | H | H | N(Et)2 | H | H | 3.85 | 3.85 | 1.93 | 1.93 | 1.93 |
|
| NO2 | H | H | Br | H | H | 3.76 | 3.76 | 0.94 | 1.88 | 1.88 |
|
| NO2 | H | H | NO2 | H | H | 4.19 | 4.19 | 2.10 | 2.10 | 4.19 |
|
| NO2 | H | OMe | OMe | H | H | 1.00 | 1.99 | 1.00 | 1.99 | 3.99 |
|
| NO2 | OMe | H | H | H | H | 4.41 | 2.21 | 4.41 | 2.21 | 2.21 |
|
| NO2 | OH | H | H | H | H | 2.32 | 4.64 | 4.64 | 2.32 | 4.64 |
|
| NH2 | H | H | Cl | H | H | 2.43 | 4.85 | 4.85 | 2.43 | 2.43 |
|
| OH | H | OMe | OMe | OMe | H | 1.99 | 3.98 | 3.98 | 1.99 | 3.98 |
| Cefadroxil | - | - | - | - | - | - | 1.72 | 1.72 | 1.72 | 1.72 | 1.72 |
* (E)-3-(4-Hydroxyphenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9a), (E)-3-(3-Nitrophenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9b), (E)-3-(3,4,5-Trimethoxyphenyl)-1-(4-Nitrophenyl)Prop-2-en-1-one (9c), (E)-3-(2-Nitrophenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9d), (E)-3-(3-Ethoxy-4-hydroxyphenyl)-1-(4-nitrophenyl)prop-2-en-1-one (9e), (E)-3-(4-Hydroxy-3-methoxyphenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9f), (E)-3-(4-(Diethylamino)phenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9g), (E)-3-(4-Bromophenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9h), (E)-1,3-Bis(4-nitrophenyl)Prop-2-en-1-one (9i), (E)-3-(3,4-Dimethoxyphenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9j), (E)-3–(2-Methoxyphenyl)-1-(4–Nitrophenyl)prop-2-en-1-one (9k), (E)-3-(2–Hydroxyphenyl)-1-(4-Nitrophenyl)prop-2-en-1-one (9l), (E)-1-(4-Aminophenyl)-3-(4-Chlorophenyl)prop-2-en-1-one (9m), and (E)-1-(4-Hydroxyphenyl)-3-(3,4,5-Trimethoxyphenyl)prop-2-en-1-one (9n).
Figure 25Important structural features of chalcones’ antibacterial activities [94].
Antibacterial activity of isoflavones and their derivatives from bark of Erythrina lysistemon.
| Compounds | MIC (μg/mL) | ||||
|---|---|---|---|---|---|
|
|
|
|
|
| |
| Erybraedin A | 1 | 2 | 2 | 2 | 20 |
| Phaseollidin | 10 | 10 | 5 | 20 | 20 |
| Abyssinone V-4′ methyl ether | 26 | 59 | 117 | 260 | 260 |
| Eryzerin C | 10 | 5 | 2 | 5 | 5 |
| Alpumisoflavone | 31 | 31 | 125 | 125 | 20 |
| Cristacarpin | 156 | 156 | 412 | 625 | 78 |
| Lysisteisoflavone | 2 | 62 | 26 | 6 | 31 |
Figure 26Structures of isoflavones and derivatives from the bark of Erythrina lysistemon and the SAR analysis of isoflavones as antibacterial agents [95].
Antibacterial activity of flavonoids from Artocarpus heterophyllus.
| Compounds | MIC (μg/mL) | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
| |
| Dihydromorin | 31.25 | 15.62 | 62.5 | 62.5 | 31.25 | - | - |
| Norartocarpetin | 125.0 | 31.25 | 250.0 | 125.0 | 250.0 | - | - |
| Ampicillin | 0.50 | 0.50 | 0.50 | 0.50 | 0.50 | 31.25 | 0.25 |
Figure 27SAR of flavonoids isolated from Artocarpus heterophyllus as antibacterial agents [96].
Antibacterial activity of carboxylated chalcones against S. aureus.
| Com. No. | R | MIC (μM) | Com. No. | R | MIC (μM) | Com. No. | R | MIC (μM) | Com. No. | R | MIC (μM) |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| H | >300 |
| 4-OPh | - |
| 3-OPh | - |
| 3,5-Di-CF3 | 2 |
|
| 4-CF3 | 150 |
| 3-CF3 | 40 |
| 2-CF3 | 300 |
| 3,5-Di-Br | 2 |
|
| 4-Cl | 150 |
| 3-Br | 75 |
| 2-Br | 150 |
| 3,5-Di-Cl | 40 |
|
| 4-Me | >300 |
| 3-Cl | 75 |
| 2-Cl | 150 |
| 3,5-Di-Me | 75 |
|
| 4-OMe | >300 |
| 3-NO2 | 300 |
| 2-OH | >300 |
| 3,5-Di-F | 150 |
|
| 4-OH | >300 |
| 3-OH | >300 |
| 2-OBu | - |
| 3,5-Di-OMe | >300 |
Control drug: Ciprofloxacin (MIC = 2 μM) and Linezolid (MIC = 2 μM). * 4-(3-Phenyl-acryloyl)-benzoic acid (10a), 4′-Carboxy-4-trifluoromethyl-chalcone (10b), 4′-Carboxy-4-chloro-chalcone (10c) 4′-Carboxy-4-methyl-chalcone (10d), 4′-Carboxy-4-methoxy-chalcone (10e), 4′-Carboxy-4-hydroxy-chalcone (10f), 4′-Carboxy-4-phenoxy-chalcone (10g), 4′-Carboxy-3-trifluoromethyl-chalcone (10h), 4′-Carboxy-3-bromo-chalcone (10i), 4′-Carboxy-3-chloro-chalcone (10j), 4′-Carboxy-3-nitro-chalcone (10k), 4′-Carboxy-3-hydroxy-chalcone (10l), 4′-Carboxy-3-phenoxy-chalcone (10m), 4′-Carboxy-2-trifluoromethyl-chalcone (10n), 4′-Carboxy-2-bromo-chalcone (10o), 4′-Carboxy-2-chloro-chalcone (10p), 4′-Carboxy-2-hydroxy-chalcone (10q), 4′-Carboxy-2-butoxy-chalcone (10r), 4′-Carboxy-3,5-bis-trifluoromethyl-chalcone (10s), 4′-Carboxy-3,5-dibromo-chalcone (10t), 4′-Carboxy-3,5-dichloro-chalcone (10u), 4′-Carboxy-3,5-dimethyl-chalcone (10v), 4′-Carboxy-3,5-difluoro-chalcone (10w), and 4′-Carboxy-3,5-dimethoxy-chalcone (10x).
Figure 28SAR of carboxylated chalcones for antibacterial activities [97].
Antibacterial activities of tested chalcones against B. bronchiseptica.
| Com. No. | R | (MIC: mg/mL) | Com. No | R | (MIC: mg/mL) | Com. No | R | (MIC: mg/mL) | Com. No | R | (MIC: mg/mL) |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
| H | 0.5 |
| 4-OMe | 0.6 |
| 2-Cl | 0.5 |
| 3-NO2 | 0.8 |
|
| 2-OH | 0.7 |
| 3,4-OMe | - |
| 3-Cl | 0.3 |
| 4-NO2 | 1.0 |
|
| 3-OH | 0.7 |
| 3-OH, 4-OMe | - |
| 4-Cl | 0.2 |
| 4-NMe2 | - |
|
| 4-OH | 0.8 |
| 2-F | - |
| 3-Br | 0.2 |
| 4-Me | 0.7 |
|
| 2-OMe | 0.5 |
| 3-F | - |
| 4-Br | - |
| 2-Me, 3,4-OMe | - |
|
| 3-OMe | 1.0 |
| 4-F | 0.4 |
| 2-NO2 | 1.0 |
* 1-(3′-Hydroxyphenyl)-3-(phenyl)-2-propen-1-one (11a), 1-(3′-Hydroxyphenyl)-3-(2-hydroxyphenyl)-2-propen-1-one (11b), 1-(3′-Hydroxyphenyl)-3-(3-hydroxyphenyl)-2-propen-1-one (11c), 1-(3′-Hydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one (11d), 1-(3′-Hydroxyphenyl)-3-(2-methoxyphenyl)-2-propen-1-one (11e), 1-(3′-Hydroxyphenyl)-3-(3-methoxyphenyl)-2-propen-1-one (11f), 1-(3′-Hydroxyphenyl)-3-(4-methoxyphenyl)-2-propen-1-one (11g), 1-(3′-Hydroxyphenyl)-3-(3,4-dimethoxyphenyl)-2-propen-1-one (11h), 1-(3′-Hydroxyphenyl)-3-(4-hydroxy,3-methoxyphenyl)-2-propen-1-one (11i), 1-(3′-Hydroxyphenyl)-2-(2-fluorophenyl)-2-propene-1-one (11j), 1-(3′-Hydroxyphenyl)-2-(3-fluorophenyl)-2-propene-1-one (11k), 1-(3′-Hydroxyphenyl)-2-(4-fluorophenyl)-2-propen-1-one (11l), 1-(3′-Hydroxyphenyl)-3-(2-chlorophenyl)-2-propen-1-one (11m), 1-(3′-Hydroxyphenyl)-3-(3-chlorophenyl)-2-propen-1-one (11n), 1-(3′-Hydroxyphenyl)-3-(4-chlorophenyl)-2-propen-1-one (11o), 1-(3′-Hydroxyphenyl)-2-(3-bromophenyl)-2-propen-1-one (11p), 1-(3′-Hydroxyphenyl)-2-(4-bromophenyl)-2-propen-1-one (11q), 1-(3′-Hydroxyphenyl)-3-(2-nitrophenyl)-2-propen-1-one (11r), 1-(3′-Hydroxyphenyl)-3-(3-nitrophenyl)-2-propen-1-one (11s), 1-(3′-Hydroxyphenyl)-3-(4-nitrophenyl)-2-propen-1-one (11t), 1-(3′-Hydroxyphenyl)-3-(4-N,N-dimethylphenyl)-2-propen-1-one (11u), and 1-(3′-Hydroxyphenyl)-3-(4-methylphenyl)-2-propen-1-one (11v), 1-(3′-Hydroxyphenyl)-3-(2-methyl-3,5-dimethoxyphenyl)-2-propen-1-one (11w).
Figure 29Important feature for chalcone containing non-polar groups to exhibit antibacterial activity against B. bronchiseptica [98].
Antibacterial activities of flavonoids and their sulfonic derivatives against several bacterial pathogens.
| Compounds | R1 | R2 | R3 | MIC (mg/mL) | |||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
| |||||||
| ATCC 25922 | Clinical Isolates | ATCC 27853 | Clinical Isolates | ATCC 29213 | Clinical Isolates | ||||
| Quercetin | H | OH | H | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 | 62.5 |
| Morin | OH | H | H | 3.9 | 3.9 | 3.9 | 62.5 | 31.2 | 31.2 |
| NaQSA | H | OH | SO3Na | 1000.0 | 62.5 | 31.2 | 1000.0 | 3.9 | 31.2 |
| NaMSA | OH | H | SO3Na | 62.5 | 31.2 | 31.2 | 31.2 | 3.9 | 31.2 |
Figure 30SAR analysis of flavonoids and their sulfonic derivatives as antibacterial agents [100].
Antibacterial activities of anthocyanins bearing fatty acid moiety in sugar portion.
| Compounds | R | MIC (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| ||||||
| ATCC 27853 | PA004 | ATCC 25922 | PA002 | ATCC 29213 | Sa1 | ATCC 29212 | S007 | ||
|
| OH | >512 | >512 | >512 | >512 | >512 | >512 | >512 | >512 |
|
|
| >512 | >512 | >512 | >512 | >512 | >512 | >512 | >512 |
|
|
| >512 | 128 | 8 | 4 | >512 | >512 | >512 | >512 |
|
|
| 256 | 32 | 2 | 2 | 128 | >512 | 8 | 8 |
|
|
| 128 | 16 | 2 | 1 | 64 | 512 | 8 | 4 |
|
|
| >512 | >512 | >512 | >512 | >512 | >512 | >512 | >512 |
* Cyanidin-3-O-glucoside (12a), cyanidin-3-O-glucoside-C4 (12b), cyanidin-3-O-glucoside-C6 (12c), cyanidin-3-O-glucoside-C8 (12d), cyanidin-3-O-glucoside-C10 (12e), and cyanidin-3-O-glucoside-C12 (12f).
Figure 31Key structural feature of cyanidin as antibacterial agent [101].
Antibacterial activity of flavone derivatives against B. subtitlis, S. aureus, and P. aeruginosa.
| Com. No. | R1 | R2 | MIC (μg/mL) | ||
|---|---|---|---|---|---|
|
|
|
| |||
|
| H | H | 12.5 | 25 | 25 |
|
| OMe | H | 50 | 50 | 37.5 |
|
| H | Br | 12.5 | 6.25 | 6.25 |
| Ciprofloxacin | - | - | 6.25 | 6.25 | 6.25 |
* 2-(4-(trifluoromethyl)phenyl)-4H-chromen-4-one (13a), 2-(4-(trifluoromethyl)phenyl)-7-methoxy-4H-chromen-4-one (13b), and 6-bromo-2-(4-(trifluoromethyl)phenyl)-4H-chromen-4-one (13c).
Figure 32The structural-activity analysis of tested flavone derivatives containing halogens [102].
Figure 33The chemical structures and the SAR of tested isoflavones [103].
Figure 34Summary from the 3D-QSAR and docking studies [104].
Figure 35The chemical structure of 2-(3′,4′-sDihydroxyphenyl)-6-nitrochromane-(4 → 4″,2 → O-5″)-phloroglucinol [105].
Figure 36The chemical structures of mentioned flavonoids [106].
Important structural characteristics of different classes of flavonoids for antibacterial activity.
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | OH ↑ | OH ↑ | C2=C3 ↑ | ||||||||
| [ | OH ↑ | OH ↑ | |||||||||
| [ | OH ↑ | Broken ring C ↑ | C=O ↑ | ||||||||
| [ | OH ↑ | OH ↑ | |||||||||
| [ | OH ↑ | Oxygenation ↑ | |||||||||
| [ | Prenyl ↑ | ||||||||||
| [ | Halogen ↑ | COOH ↑ | |||||||||
| [ | Bromine ↑ | ||||||||||
| [ | Lipophilic subtituent ↑ | ||||||||||
| [ | Lipophilic subtituent ↑ | ||||||||||
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | OH ↑ | Geranyl ↑ | OMe ↓ | OMe ↓ | OMe ↓ | ||||||
| [ | Two hydroxyl groups ↑ | Absence of hydroxyl groups ↑ | |||||||||
| [ | OH ↑ | C=O ↑ | |||||||||
| [ | OH ↑ | OH ↑ | Trihydroxylation ↑ | Saturation of C2=C3 ↑ | |||||||
| [ | Saturation of C2=C3 ↑ | ||||||||||
| [ | Glycosyl ↑ | ||||||||||
| [ | C2=C3 ↓ | ||||||||||
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | OH ↑ | OH ↓ | OMe ↑ | OH ↓ | OH ↑ | OH ↓ | OH ↓ | ||||
| [ | OH ↑ | OH ↑ | OH ↑ | C2=C3 ↑ | OH ↑ | ||||||
| [ | OMe ↑ | OH ↑ | |||||||||
| [ | OH ↑ | OH ↑ | OH ↑ | OH ↑ | OH ↑ | ||||||
| [ | OMe ↑ | OMe ↑ | NO2 ↓ | ||||||||
| [ | Two hydroxyl groups ↑ | Absence of hydroxyl groups ↑ | C2=C3 ↑ | ||||||||
| [ | Prenyl ↑ | OMe ↑ | |||||||||
| [ | OH ↑ | ||||||||||
| [ | OH ↑ | OH ↑ | Trihydroxylation ↑ | ||||||||
| [ | OH ↑ | OH ↑ | OH ↑ | Sulfo ↑ | |||||||
| [ | Halogen ↑ | CF3 ↑ | |||||||||
| [ | OH ↑ | OH ↓ | OH ↑ | OMe ↓ | C2=C3 ↑ | OH ↑ | |||||
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | Glycosyl ↓ | Glycosyl ↓ | |||||||||
| [ | OH ↑ | OH ↑ | OH ↑ | OMe ↓ | OH ↑ | ||||||
| [ | Prenyl ↑ | Prenyl ↑ | |||||||||
| [ | OH ↑ | Prenyl ↑ | |||||||||
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | OH ↑ | OH ↑ | OH ↑ | Long acyl chain ↑ | |||||||
| [ | OH ↑ | ||||||||||
|
| |||||||||||
|
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
| |
| [ | Glycosyl ↑ | ||||||||||
| [ | Electron withdrawing group ↑ | ||||||||||
* ↑ indicates the substitution of mentioned moieties can increase flavonoids’ antibacterial activities. ↓ indicates the substitution of mentioned groups can reduce flavonoids’ antibacterial activities.